News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Diego Díaz García: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials
Diego A. Díaz García/X
Jun 22, 2025, 11:09

Diego Díaz García: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials

Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, posted on X:

“Are we overestimating success in ph3 oncology trials?
Only 6% of ph3 oncology RCTs show improvement in both OS and QoL.
Most “positive” trials rely on surrogate endpoints, often without adjusting QoL for baseline. We must refocus trials on what truly matters to patients.”

Title: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials

Authors: Alexander D. Sherry, Avital M. Miller, Jnana Preeti Parlapalli, Gabrielle S. Kupferman, Esther J. Beck, Jordan McDonald, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, Nina N. Sanford, Fumiko Chino, Bishal Gyawali, Christopher Booth, Pavlos Msaouel, Ethan B. Ludmir

Read The Full Article at JAMA Oncology.

Diego Díaz García: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials

More posts featuring Diego Díaz García.

Alexander D. Sherry Avital M Miller Bishal Gyawali cancer Christopher Booth Diego Díaz García Esther J Beck Ethan B Ludmir Fumiko Chino Gabrielle S Kupferman Jnana Preeti Parlapalli Jordan McDonald Joseph Abi Jaoude Nina N. Sanford OncoDaily Oncology Pavlos Msaouel Ramez Kouzy Timothy A Lin
Special Coverage
Blog
Jul 11, 2025, 19:32
Jill Feldman: EQUAL Study Spotlight
Blog
Jul 11, 2025, 19:23
Yüksel Ürün: Science Is Better When It’s Shared
Insight
Jul 11, 2025, 19:07
Khushali Jhaveri: Where Lymphoma History Met Its Future
Insight
Jul 11, 2025, 18:59
Mario Balsa: New Nature Study on Lung Cancer in Never Smokers Reveals Key Mutational Forces
Blog
Jul 11, 2025, 18:45
Ed Esplin: Is There Any Patient Who Should Not Have Germline Genetic Testing to Aid Treatment Decision Making?
Insight
Jul 11, 2025, 18:40
Paolo Tarantino: A Recap of the Epic Journey of HER2 as a Biomarker Over the Past 30 years
Blog
Jul 11, 2025, 18:21
Aparna Parikh: You will be Deeply Missed by Your Mass General Cancer Center GI Oncology Family
Blog
Jul 11, 2025, 18:04
ASPIRE for Lung Cancer - Introducing the APAC Lung Cancer Consensus Video Series
Blog
Jul 11, 2025, 17:52
Asia-Pacific Gastroenterology Cancer Summit - Multidisciplinary Collaboration in the Management of Pancreatic Cancer
Blog
Jul 11, 2025, 17:42
Biomarkers and Precision Oncology Forum - Uncover Breakthroughs at the Frontlines of Lung Cancer Care
Blog
Jul 11, 2025, 17:32
Paolo Ascierto: Strategic Innovation in Oncology - Immunotherapy Before Surgery
Blog
Jul 11, 2025, 17:27
Debra Patt: The Power of Technology in Improving Patient Incomes